NSE: ABBOTINDIA | BSE: 500488

Expensive Performer

Download real time

32845.00 125.00 (0.38%)

29.69% Gain from 52W Low

3,257 NSE+BSE Volume

NSE 08 Aug, 2025 3:31 PM (IST)

69,793.3

Market Cap

High in industry

0.5

Beta 1Year

Very Low volatility

Board Meeting

The next board meeting for Abbott India Ltd. is on 12 Aug 2025 for the purpose of Quarterly Results See details

Abbott India Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for ABBOTINDIA, BSE:500488 Abbott India Ltd.

Search Inside the pdf :

Abbott India Ltd.

04 Jul 2025

32845.00

0.38%

Abbott India (BUY): Ascribing valuation in line with its peer GSK

Buy: Abbott India Ltd.

Target

BOB Capital Markets Ltd.

Novo's oral semaglutide Rybelsus is growing at a robust 173% CAGR over a 3Y period to Rs 4bn, as on MAT MAY'25

Abbott India Ltd. has an average target of 35626.00 from 3 brokers.

Abbott India Ltd.

16 May 2025

32845.00

0.38%

Sustained improvement across the board

Buy: Abbott India Ltd.

Target

ICICI Securities Limited

Abbott India’s (Abbott) revenue grew 12% YoY ahead of most MNCs (avg. growth of ~10% YoY and IPM growth of ~8% YoY in Q4FY25). Abbott’s growth was aided by healthy traction in its own brands along with key brands of Novo Nordisk like Rybelsus and Ryzodeg.

Abbott India Ltd. has an average target of 35626.00 from 3 brokers.

Abbott India Ltd.

29 Apr 2025

32845.00

0.38%

ERRATA: Abbott India (BUY): Mixtard discard to result in highest-ever EBITDA margin

Buy: Abbott India Ltd.

BOB Capital Markets Ltd.

Novo Nordisk insulin brand outgo to result in 330 bps and 670 bps increase in EBITDA margin to 30.9% and 34.9% for FY26E and FY27E

Abbott India Ltd. is trading below its 30 day SMA of 34221.0

Abbott India Ltd.

11 Apr 2025

32845.00

0.38%

[Initiation] Abbott India (BUY): A safe pick amidst tariff woes

Buy: Abbott India Ltd.

BOB Capital Markets Ltd.

Sales expected to reach USD 1bn, driven by industry-leading MR productivity of Rs 14.9mn by FY27E from Rs 11.5mn in FY24

Abbott India Ltd. has an average target of 35626.00 from 3 brokers.

Abbott India Ltd.

06 Feb 2025

32845.00

0.38%

Stellar quarter; growth pace accelerating

Buy: Abbott India Ltd.

Target

ICICI Securities Limited

Abbott India’s (Abbott) impressive revenue growth of 12.3% YoY in Q3FY25 was ahead of our expectation. As per IQVIA, this may be driven by key brands of Novo Nordisk like Rybelsus and Ryzodeg and owned brands like Duphalac, Udiliv and Thyronorm.

Abbott India Ltd. is trading above its 200 day SMA of 30200.2

Abbott India Ltd.

06 Feb 2025

32845.00

0.38%

Result Update:Abbott India

Buy: Abbott India Ltd.

Target

Axis Direct

We maintain a BUY rating on the stock

Abbott India Ltd. has an average target of 35626.00 from 3 brokers.

Abbott India Ltd.

08 Nov 2024

32845.00

0.38%

Result Update:Abbott India

Buy: Abbott India Ltd.

Axis Direct

we maintain a BUY rating on the stock. We have set a target price of Rs 31,420/share, which implies an upside potential of 12% from the CMP.

Abbott India Ltd. is trading below its 30 day SMA of 34221.0

Abbott India Ltd.

26 Oct 2024

32845.00

0.38%

Pick of the Week:28 October 2024

Buy: Abbott India Ltd.

Target

Axis Direct

We recommend a BUY with a target price of Rs 31,420/share (46.5x P/E for FY26E), implying an upside of 10% from the CMP.

Abbott India Ltd. is trading below its 30 day SMA of 34221.0

Abbott India Ltd.

08 Aug 2024

32845.00

0.38%

Healthy earnings: growth momentum to continue

Buy: Abbott India Ltd.

Target

Sharekhan

Earnings were in line with our estimates, where sales grew by 5% y-o-y to Rs 1,557 crore (1.6% below our estimates), EBITDA grew by 10% y-o-y to Rs 3,910 crore.